Stoke Therapeutics, Inc. STOK Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $155.66M+84.8% | $84.22M+1.0% | $83.39M-17.8% | $101.47M-63.1% | $274.82M+115% | ||
| $187.89M-6.3% | $200.45M+21.5% | $164.92M+12.8% | $146.24M+77.2% | $82.51M— | ||
| —— | —— | —— | —— | $3.02M+77.0% | ||
| $366.68M+19.9% | $305.7M+12.2% | $272.44M+0.9% | $269.97M-28.1% | $375.74M+61.4% | ||
| $3.4M+7.9% | $3.15M+2.0% | $3.08M-7.8% | $3.34M-7.4% | $3.61M-7.6% | ||
| $443.28M+5.9% | $418.43M+16.1% | $360.26M-6.3% | $384.51M-5.5% | $406.89M+49.8% | ||
| $6.84M+38.5% | $4.94M-15.9% | $5.87M+36.1% | $4.31M+97.3% | $2.19M-12.5% | ||
| $6.6M-5.1% | $6.96M— | —— | —— | —— | ||
| $40.81M-29.5% | $57.88M+38.7% | $41.73M+7.9% | $38.68M-13.4% | $44.69M+11.6% | ||
| $7.59M-6.3% | $8.1M-22.3% | $10.43M-4.2% | $10.89M-10.2% | $12.13M+389% | ||
| $48.4M-26.6% | $65.98M+26.5% | $52.16M+5.2% | $49.57M-12.8% | $56.81M+33.6% | ||
| $6K+20.0% | $5K0.0% | $5K0.0% | $5K0.0% | $5K0.0% | ||
| -$547.72M-10.0% | -$497.72M-13.2% | -$439.78M-9.6% | -$401.43M-6.2% | -$377.95M+23.0% | ||
| $394.88M+12.0% | $352.46M+14.4% | $308.11M-8.0% | $334.94M-4.3% | $350.07M+52.9% | ||
| $443.28M+5.9% | $418.43M+16.1% | $360.26M-6.3% | $384.51M-5.5% | $406.89M+49.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Stoke Therapeutics, Inc. cover its short-term obligations?
- Its current ratio is 8.99 — current assets exceed current liabilities.
- Where does Stoke Therapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.